EXTON, Pa., Oct. 8, 2018 /PRNewswire/ -- West
Pharmaceutical Services, Inc. (NYSE: WST), a global leader in
innovative solutions for injectable drug administration, today
announced that it will introduce a new Integrated Solutions Program
to help to reduce risk, mitigate regulatory complexity and simplify
the journey from molecule to market for pharmaceutical partners at
the PDA Universe of Prefilled Syringes and Injection Devices (PDA)
and CPhI Worldwide conferences. In addition, West will highlight
its industry expertise through a number of technical- and
regulatory-focused PDA presentations.
West's new Integrated Solutions Program will provide customers
with a comprehensive approach to drug containment and delivery
system development. Available in defined and customized packages,
the new offering will combine West's suite of drug packaging and
delivery products with West's proven expert testing and support
services, to meet the unique needs of the drug product and its
delivery system at any stage of development, across all injectable
formats.
"Our customers are under increasing pressure to move new
therapies to market quickly while maintaining cost efficiencies –
all while enduring increased regulatory scrutiny," said
Karen Flynn, SVP & Chief
Commercial Officer, West. "West's new Integrated Solutions Program
will allow our customers to efficiently leverage our extensive
knowledge of primary containment and delivery systems and advanced
analytical testing capabilities to manage the regulatory landscape
while helping to reduce development and supply risk, accelerate
path to market, minimize total cost of ownership and improve the
patient experience."
While the Integrated Solutions Program is new, West has
well-established quality and regulatory expertise, which will be
featured in the following poster and panel presentations at
PDA:
- October 8—3:45 to 5:15
p.m.—B2: Building Clarity in Addressing Regulatory
Challenges for Combination Products, Moderated by Fran DeGrazio, Vice President, Scientific
Affairs & Technical Services, West
- October 8—3:15 to 3:45
p.m.—What's New with the Regulations? A
Well-Rounded Approach to Regulatory Performance Testing for
Combination Products, Daniel L. Bantz, Technology Manager,
West
- October 9—7:15 to 7:40
a.m.—Impact of Excipients on Functionality,
Liang Fang, Principal Research
Scientist, West (co-presented with Galen
Shi, PhD, Advisor, Eli Lilly and Company)
- October 8 and October
9—10:00 to 10:45 a.m. and 3:00 to
3:45 p.m.—Gx RTF® syringes and
NovaPure™ plunger stoppers, Katie
Espenshade, SME Specialist, CZ, PDS, Combination Products,
West (co-presented with Maximilian Vogl, Global Head of Product
Management Gx® Solutions, Gerresheimer)
At CPhI Worldwide, in recognition of West's enduring commitment
to both quality and corporate sustainability, West will be
highlighted as a finalist in the CPhI Awards for Excellence in
Pharma for the categories of Supply Chain, Logistics and
Distribution and Corporate Social Responsibility. The CPhI Awards
for Excellence in Pharma celebrate companies that turn inspiration
into innovation to drive the pharmaceutical industry
forward.
In addition to showcasing its full portfolio of drug containment
and delivery technologies, West will also introduce Daikyo's D
Sigma® stoppers at CPhI Worldwide. Available in
Ready-to-Use-Validated (RUV®) and Ready-to-Sterilize-Validated
(RSV®) formats, Daikyo D Sigma high-quality elastomer components
combine advanced technology and expertise to provide the tightest
particulate specification in the Daikyo portfolio and 100 percent
dimensional verification, helping to reduce variability and
mitigate potential risks to patient safety.
For more information on West products and services, including
Daikyo Crystal Zenith® containment & delivery systems, its
Westar® Select quality enhancement offering, NovaPure™ components,
SelfDose™ patient-controlled injector and SmartDose™ drug delivery
platform, visit Booth #506 at PDA Universe of Prefilled Syringes
and Injection Devices, October 8-9,
in Orlando, FL; Booth #4C22 at
CPhI Worldwide October 9-11, in
Madrid, Spain; or West online at
www.westpharma.com.
Forward-Looking Statements
Certain forward-looking
statements are included in this press release. They use such
words as "will," "new," "proven," "allow," "reduce," "accelerate,"
"minimize," "improve" and other similar terminology. These
statements reflect management's current expectations regarding
future events and operating performance and speak only as of the
date of this release. There is no certainty that actual
results will be achieved in-line with current expectations or that
the services will achieve any particular result. These
forward-looking statements involve a number of risks and
uncertainties. The following are some of the factors that
could cause our actual results to differ materially from those
expressed in or underlying our forward-looking statements: customer
decisions to move forward with our new service offerings and the
ability to meet development milestones with key customers.
These important factors are not all inclusive. For a description of
certain additional factors that could cause the Company's future
results to differ from those expressed in any such forward-looking
statements, see Item 1A, entitled "Risk Factors," in the Company's
Annual Report on Form 10-K for the year ended December 31, 2017. Except as required by law or
regulation, we undertake no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is a
leading manufacturer of packaging components and delivery systems
for injectable drugs and healthcare products. Working by the side
of its customers from concept to patient, West creates products
that promote the efficiency, reliability and safety of the world's
pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its
customers from locations in North and South America, Europe, Asia
and Australia. West's 2017 net
sales of $1.6 billion reflect the
daily use of approximately 112 million of its components and
devices, which are designed to improve the delivery of healthcare
to patients around the world.
West and the diamond logo, Westar®, NovaPure™ and
SelfDose™ are registered trademarks or trademarks of West
Pharmaceutical Services, Inc., in the
United States and other jurisdictions.
SmartDose™ is a trademark of West Pharma. Services IL, Ltd, a
subsidiary of West Pharmaceutical Services, Inc.
Daikyo D Sigma®, RUV®, RSV®, and Crystal Zenith® are
registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal
Zenith® technology is licensed from Daikyo Seiko, Ltd.
RTF® is a registered trademark of Gerresheimer Bunde
GmbH.
Gx® is a registered trademark of Gerresheimer Glas
GmbH.
Media Contact:
Michele Pelkowski
Senior Director, Global Communications
+1-610-594-3054
Michele.Pelkowski@westpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/west-highlights-integrated-solutions-offering-and-related-technical-and-regulatory-expertise-at-upcoming-industry-events-300725369.html
SOURCE West Pharmaceutical Services, Inc.